This study is currently not recruiting participants.
The Efficacy and Safety of Bimatoprost Sustained Release
Not Recruiting
18 years - 99 years
All
Phase
3
1 Location
Brief description of study
The purpose of this study is to investigate the safety and effectiveness of two different dose strengths in lowering eye pressure in subjects with glaucoma or high eye-pressure.The Bimatoprost sustained release (SR) is a small implant placed inside the eye. It dissolves naturally in the body and contains the bimatoprost drug. The drug is slowly released for about 3 to 4 months.
Detailed description of study
All subjects who take part in this study will get Timolol 0.5% eye drops to use in the eye(s) that do not receive Bimatoprost SR.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Glaucoma, Hypertension, hypertension, Open-Angle Glaucoma, ocular
-
Age: 18 years - 99 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 821753
Message For Non Enrolling By Invitation Trial
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or